Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim is fully supported by FDA label language for fetal toxicity/pregnancy, including second/third trimester risk, pregnancy-triggered discontinuation/alternative therapy, and the lifesaving exception when no alternatives exist.
Category Scores
Accurate Statements
ENTRESTO can cause fetal harm when administered during pregnancy, particularly in the second and third trimesters.
Supported by Label 5.1 ("ENTRESTO can cause fetal harm"; second and third trimesters reduce fetal renal function and increase morbidity/death) and Label 8.1 (Risk Summary).
Pregnancy should prompt discontinuation and consideration of alternative therapy (with lifesaving exceptions).
Supported by Label 5.1 (consider alternative and discontinue when pregnancy is detected; exception if no alternative and therapy is lifesaving) and Label 8.1 (same risk management language).
Unsupported Statements
Contradictions
Important Omissions
The AI claim does not mention the specific fetal/neonatal adverse outcomes and monitoring/management details (e.g., oligohydramnios-related findings, serial ultrasound, neonatal hypotension/oliguria/hyperkalemia, and possible dialysis/exchange transfusions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statement correctly reflects the label’s core pregnancy/fetal toxicity warning and associated management trigger (discontinue and consider alternatives, with a lifesaving/no-alternative exception).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omitted label-specific clinical details (fetal/neonatal adverse reaction types and suggested monitoring/management) that are present in Section 8.1.
Suggested Improvement
If expanding beyond the core warning, include key Section 8.1 details such as oligohydramnios-related consequences, serial ultrasound and fetal testing considerations, and neonatal monitoring/management for hypotension, oliguria, and hyperkalemia.